Streetbeat News

Regulatory

ARAY

Accuray Incorporated (NASDAQ:ARAY) has received approval from the Chinese National Medical Products Administration for its Precision Treatment Planning System. This approval allows the system to be used with the CNNC-Accuray joint venture Tomo® C radiation therapy system, expanding cancer care options in China.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 11:39 am

AAPL

BIDU

Apple Inc. (NASDAQ:AAPL) is working to introduce its AI technology, Apple Intelligence, in China despite stringent regulations. Craig Federighi, Apple's senior VP of software engineering, acknowledged the challenges but confirmed the company's efforts. This move is crucial as China is Apple's second-largest market, and the company faces fierce competition from local companies. Rivals like Samsung and Lenovo have teamed up with Baidu Inc. (NASDAQ:BIDU) to offer AI-powered features in China.

Portfolio Pulse from Rounak Jain

June 12, 2024 | 11:38 am

LTRN

Lantern Pharma announced that the Japan Patent Office has issued a certificate of patent for the composition of matter covering their drug candidate LP-284.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 11:34 am

PTN

Palatin Technologies has initiated a Phase 2 trial to evaluate the combined efficacy of bremelanotide and tirzepatide in managing obesity. Topline data is expected by the end of 2024, with additional studies being considered for other metabolic conditions.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 11:34 am

AAPL

AVGO

CASY

ORCL

OXM

PLAY

QQQ

SPY

The market is poised for further gains, with the S&P 500 and Nasdaq Composite hitting record highs. Investors are focused on the upcoming inflation report and the Federal Reserve's rate decision. Oracle's positive earnings may support tech stocks, while Apple led the tech charge in the previous session. Key economic data and Fed commentary will be crucial for market direction.

Portfolio Pulse from Shanthi Rexaline

June 12, 2024 | 11:26 am

RNA

Avidity Biosciences reported over 50% reduction in DUX4 regulated genes in its Phase 1/2 FORTITUDE trial for facioscapulohumeral muscular dystrophy (FSHD). The company plans to accelerate the initiation of registrational cohorts. The investigational therapy, delpacibart braxlosiran (AOC 1020), showed promising results in muscle strength and patient outcomes, with favorable safety and tolerability.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 11:13 am

SPY

USO

VGK

Iraq's Oil Ministry has announced its commitment to a quota of 203,000 barrels for May 2024, as reported by Reuters.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 11:08 am

ERO

Ero Copper has received the operational license for the Tucumã Project, marking the final permitting milestone for commercial operation.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 11:05 am

DNTH

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has received FDA clearance to initiate a Phase 2 trial for its drug DNTH103, aimed at treating Multifocal Motor Neuropathy (MMN).

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 11:03 am

AAPL

Apple Inc. (NASDAQ:AAPL) announced that users can opt out of OpenAI's ChatGPT integration, addressing privacy concerns. This decision follows Elon Musk's criticism of AI privacy issues and threats to ban Apple devices from Tesla and SpaceX. Apple also introduced its in-house AI suite and iOS 18 update at the Worldwide Developers Conference.

Portfolio Pulse from Rounak Jain

June 12, 2024 | 10:37 am